Home-Products- PLLA Filler - PLLA Hydrogel Filler-

Content

PLLA Skin Booster

PLLA Skin Booster

Unlike traditional hyaluronic acid (HA) dermal fillers that rely on a hydrophilic gel matrix for immediate volumetric correction, PLLA-based injectables serve a different clinical objective: the gradual stimulation of endogenous collagen production and progressive improvement of skin texture.

PRODUCT INTRODUCTION

PRODUCT INTRODUCTION

PLLA Skin Booster is an injectable medical aesthetic product formulated with poly-L-lactic acid (PLLA), a biocompatible and biodegradable synthetic polymer.

 

Unlike traditional hyaluronic acid (HA) dermal fillers that rely on a hydrophilic gel matrix for immediate volumetric correction, PLLA-based injectables serve a different clinical objective: the gradual stimulation of endogenous collagen production and progressive improvement of skin texture.

 

Technical Specifications

 

Parameter

Specification Details

Product Name

PLLA Skin Booster

Active Material

Poly-L-Lactic Acid (PLLA)

Product Classification

Injectable aesthetic medical device

Formulation Type

Lyophilized powder / sterile presentation*

Container

Medical-grade glass vial with rubber stopper and seal*

Primary Indication

Skin rejuvenation and collagen biostimulation

Target Treatment Areas

Facial skin and designated aesthetic application sites*

Sterility

Sterilized in accordance with medical device standards*

Shelf Life & Storage

Confirm via official stability data and product documentation*

Customization / OEM

Available subject to project evaluation and regulatory requirements

 

Application Positioning and Treatment Scope

 

PLLA Skin Booster is integrated into clinical protocols where the primary goal is improving dermal quality rather than mechanical volumization.

 

Facial Skin Rejuvenation: Applied in treatment programs targeting compromised skin density, loss of elasticity, and fine lines.

 

Structural Firmness: Positioned for protocols requiring sustained improvement in skin architecture over multiple treatment sessions.

 

Extended Application Areas: Depending on local regulatory approvals and approved IFUs, PLLA-based formulations may be evaluated for auxiliary treatment sites such as the neck, décolletage, or dorsum of the hands.

 

All application depths, reconstitution guidelines, and treatment intervals must strictly adhere to the approved IFU and destination-market regulations.

 

Raw Material and Formulation Controls

 

For injectable PLLA products, formulation integrity directly dictates suspension behavior, injection smoothness, and in-vivo performance. Manufacturing controls focus heavily on raw material and process parameters:

 

PLLA Raw Material Specification: Strict selection of medical-grade PLLA raw material to ensure batch consistency. Parameters monitored include polymer chain characteristics, molecular weight distribution, purity levels, residual solvents, bioburden, and endotoxin limits.

 

Particle Characteristics: Particle size distribution and morphology are precisely controlled to govern reconstitution speed, suspension stability, extrusion force, cannula compatibility, and uniform dispersion within the target tissue.

 

Lyophilization Process: For lyophilized presentations, freeze-drying parameters-including primary and secondary drying cycles, residual moisture limits, and cake appearance-are validated to guarantee consistent reconstitution performance and long-term stability.

 

Comprehensive Quality Control System

 

Raw Material Testing: Identity verification, purity assays, and rigorous supplier qualification.

 

In-Process Controls: Environmental monitoring in cleanroom facilities, precise fill volume measurement, and strict control over solution preparation parameters.

 

Finished Product Testing: Verification of appearance, fill weight, reconstitution time, sterility assurance, bacterial endotoxins, particulate matter limits, container-closure integrity, and real-time stability testing.

 

Traceability: Full batch-record documentation linking raw material lots to finished commercial product release.

 

Sterile Manufacturing Infrastructure

 

Production capabilities for medical biomaterials and injectable devices require controlled cleanroom environments and validated sterilization pathways.

 

The manufacturing sequence follows a controlled operational workflow:

Raw Material → Formulation → Aseptic Filling → Lyophilization → Stoppering → Sterility Assurance → Inspection → Packaging → Batch Release

 

Commercial Supply and Private Label Options

 

To accommodate diverse market entry strategies, the product is available under flexible supply models:

 

Standard Supply: Delivery of established product configurations supported by comprehensive technical documentation packages, Certificate of Analysis (COA), and batch records.

 

OEM / Private Label Solutions: Tailored for aesthetic brands developing proprietary product lines. Customization scopes include:

 

  • Brand naming and proprietary vial labeling
  • Custom folding carton artwork and design
  • Tailored Instructions for Use (IFU)
  • Market-specific secondary packaging configurations

 

Private label feasibility depends on regulatory classifications, order volume, and destination-market compliance requirements.

 

FAQ

 

Q: What is a PLLA Skin Booster?

A: It is an injectable aesthetic device based on poly-L-lactic acid designed primarily for skin rejuvenation and collagen biostimulation, rather than immediate volumetric correction.

Q: How does a PLLA Skin Booster differ from a PLLA dermal filler?

A: While both utilize poly-L-lactic acid, they differ in formulation concentration, particle specifications, reconstitution requirements, and intended clinical application depth.

Q: Is the product supplied in a ready-to-use syringe?

A: Lyophilized powder formulations require reconstitution with an appropriate diluent following the approved IFU prior to administration.

Q: What documentation is provided with commercial shipments?

A: Shipments include the product specification sheet, Certificate of Analysis (COA), batch traceability data, and packaging specifications.

Q: Are private label and OEM customization options available?

A: Yes. OEM services can be structured for qualified partners, covering customized labeling, packaging design, and documentation alignment based on target market regulations.

Q: How is Minimum Order Quantity (MOQ) determined?

A: MOQ varies depending on whether the order utilizes standard specifications or custom OEM packaging configurations. Consult the commercial team for specific project parameters.

Hot Tags: plla skin booster, China plla skin booster manufacturers, suppliers, factory

SEND INQUIRY

SEND INQUIRY